A Phase 2 interventional study of HRS9531 injection and HRS9531 injection Placebo in Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-07.
Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ribupatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. ribupatide · Diabetes Mellitus, Type 2.
Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is the only one in phase 2, and was the 4th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 11 studies testing ribupatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 199 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 72 across the 11 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
This study is registered under Fujian Shengdi Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.
81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd.: 8 open now, 11 under way, 4 of them phase 3. Of 50 finished, 0 (0%) have results posted.
Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 22nd largest by enrollment, is one of 10 that started in 2023, is one of 15 in phase 2, and was the 50th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Diabetes Mellitus, Type 2 studies by the year they started, since 2011.
1 of the studies testing ribupatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 81 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HRS9531 injection dose level 1
Drug: HRS9531 injection
HRS9531 injection dose level 2
Drug: HRS9531 injection
HRS9531 injection dose level 3
Drug: HRS9531 injection
HRS9531 injection dose level 4
Drug: HRS9531 injection
HRS9531 injection Placebo dose level 1
Drug: HRS9531 injection Placebo
HRS9531 injection Placebo dose level 2
Drug: HRS9531 injection Placebo
HRS9531 injection Placebo dose level 3
Drug: HRS9531 injection Placebo
HRS9531 injection Placebo dose level 4
Drug: HRS9531 injection Placebo
single dose
single dose
Change From Baseline in HbA1c after 20 weeks of treatment
Time frame: Week 0 to Week 20
Proportion of subjects reaching HbA1c targets (HbA1c<7.0%) after 20 weeks of treatment
Time frame: Week 0 to Week 20
Proportion of subjects reaching HbA1c targets (HbA1c<7.0%) after 32 weeks of treatment
Time frame: Week 0 to Week 32
Change From Baseline in HbA1c after 32 weeks
Time frame: Week 0 to Week 32
Change from baseline in fasting plasma glucose (FPG), serum insulin and C-peptide after 20 weeks of treatment
Time frame: Week 0 to Week 20
Change from baseline in fasting plasma glucose (FPG), serum insulin and C-peptide after 32 weeks of treatment
Time frame: Week 0 to Week 32
Change from baseline body Weight and waist circumference after 20 weeks of treatment
Time frame: Week 0 to Week 20
Change from baseline in body Weight and waist circumference after 32 weeks of treatment
Time frame: Week 0 to Week 32
Number of Participants With Anti-HRS9531 Antibody
Time frame: Week 0 to Week 36
Number of AEs During the Trial
Time frame: Week 0 to Week 36
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Sep 2024, 13 months.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribupatide
Fujian Shengdi Pharmaceutical Co., Ltd. →